Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study

Journal of the American College of Cardiology

Volumn 68, Issue 6, 2016, Pages 589-599

  Van Belle, Eric ^a   Hengstenberg, Christian ^b,c   Lefevre, Thierry ^d   Kupatt, Christian ^e   Debry, Nicolas ^a   Husser, Oliver ^b   Pontana, François ^a   Kuchcinski, Grégory ^a   Deliargyris, Efthymios N ^f   Mehran, Roxana ^g   Bernstein, Debra ^f   Anthopoulos, Prodromos ^h   Dangas, George D ^g  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^e UNIVERSITY OF MUNICH   (Germany)

^f MEDICINES COMPANY   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h Medicines Company   (Switzerland)

Author keywords

stenosis; stroke; valvuloplasty

Indexed keywords

HEPARIN; HIRULOG; ANTITHROMBIN; BIVALIRUDIN; FIBRINOLYTIC AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN DAMAGE; BRAIN EMBOLISM; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT PLANNING; VERY ELDERLY; ADVERSE EFFECTS; AORTIC VALVE STENOSIS; BRAIN; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; INTRACRANIAL EMBOLISM; PATHOLOGY; PEROPERATIVE COMPLICATION; PROSPECTIVE STUDY;

AGED, 80 AND OVER; ANTITHROMBINS; AORTIC VALVE STENOSIS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEPARIN; HIRUDINS; HUMANS; INTRACRANIAL EMBOLISM; INTRAOPERATIVE COMPLICATIONS; MAGNETIC RESONANCE IMAGING; MALE; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84992065884     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.05.006     Document Type: Article

References (30)

1. 1 Makkar, R.R., Fontana, G.P., Jilaihawi, H., et al., for the PARTNER Trial Investigators. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 366 (2012), 1696–1704.
2. 2 Adams, D.H., Popma, J.J., Reardon, M.J., et al., for the CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370 (2014), 1790–1798.
3. 3 Hamm, C.W., Mollmann, H., Holzhey, D., et al., for the GARY-Executive Board. The German Aortic Valve Registry (GARY): in-hospital outcome. Eur Heart J 35 (2014), 1588–1598.
4. 4 Ghanem, A., Muller, A., Nahle, C.P., et al. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol 55 (2010), 1427–1432.
5. 5 Kahlert, P., Knipp, S.C., Schlamann, M., et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation 121 (2010), 870–878.
6. 6 Arnold, M., Schulz-Heise, S., Achenbach, S., et al. Embolic cerebral insults after transapical aortic valve implantation detected by magnetic resonance imaging. J Am Coll Cardiol Intv 3 (2010), 1126–1132.
7. 7 Astarci, P., Glineur, D., Kefer, J., et al. Magnetic resonance imaging evaluation of cerebral embolization during percutaneous aortic valve implantation: comparison of transfemoral and trans-apical approaches using Edwards Sapiens valve. Eur J Cardiothorac Surg 40 (2011), 475–479.
8. 8 Lansky, A.J., Schofer, J., Tchetche, D., et al. A prospective randomized evaluation of the TriGuard HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J 36 (2015), 2070–2078.
9. 9 Knecht, S., Oelschlager, C., Duning, T., et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 29 (2008), 2125–2132.
10. 10 Vermeer, S.E., Prins, N.D., den Heijer, T., Hofman, A., Koudstaal, P.J., Breteler, M.M., Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348 (2003), 1215–1222.
11. 11 Thourani, V.H., Kodali, S., Makkar, R.R., et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 387 (2016), 2218–2225.
12. 12 Van Mieghem, N.M., Schipper, M.E., Ladich, E., et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation 127 (2013), 2194–2201.
13. 13 Van Mieghem, N.M., El Faquir, N., Rahhab, Z., et al. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. J Am Coll Cardiol Intv 8 (2015), 718–724.
14. 14 Breyne, J., Juthier, F., Corseaux, D., et al. Atherosclerotic-like process in aortic stenosis: activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. Atherosclerosis 213 (2010), 369–376.
15. 15 Dangas, G.D., Lefevre, T., Kupatt, C., et al., for the BRAVO-3 Investigators. Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement: the randomized BRAVO-3 trial. J Am Coll Cardiol 66 (2015), 2860–2868.
16. 16 Sergie, Z., Lefevre, T., Van Belle, E., et al. Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. J Thromb Thrombolysis 35 (2013), 483–493.
17. 17 Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
18. 18 Nashef, S.A., Roques, F., Michel, P., Gauducheau, E., Lemeshow, S., Salamon, R., European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 16 (1999), 9–13.
19. 19 Wendt, D., Kleinbongard, P., Knipp, S., et al. Intraaortic Protection from embolization in patients undergoing transaortic transcatheter aortic valve implantation. Ann Thorac Surg 100 (2015), 686–691.
20. 20 Haussig, S., Mangner, N., Dwyer, M.G., et al. Effect of a cerebral protection device on brain lesions following TAVI in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial. JAMA, 2016 In press.
21. 21 Vogt, G., Laage, R., Shuaib, A., Schneider, A., VISTA Collaboration. Initial lesion volume is an independent predictor of clinical stroke outcome at day 90: an analysis of the Virtual International Stroke Trials Archive (VISTA) database. Stroke 43 (2012), 1266–1272.
22. 22 Luby, M., Bykowski, J.L., Schellinger, P.D., Merino, J.G., Warach, S., Intra- and interrater reliability of ischemic lesion volume measurements on diffusion-weighted, mean transit time and fluid-attenuated inversion recovery MRI. Stroke 37 (2006), 2951–2956.
23. 23 Gilard, M., Eltchaninoff, H., Iung, B., et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 366 (2012), 1705–1715.
24. 24 Mastoris, I., Schoos, M.M., Dangas, G.D., Mehran, R., Stroke after transcatheter aortic valve replacement: incidence, risk factors, prognosis, and preventive strategies. Clin Cardiol 37 (2014), 756–764.
25. 25 Drews, T., Pasic, M., Buz, S., et al. Transcranial Doppler sound detection of cerebral microembolism during transapical aortic valve implantation. Thorac Cardiovasc Surg 59 (2011), 237–242.
26. 26 Barbanti, M., Gulino, S., Tamburino, C., Capodanno, D., Antithrombotic therapy following transcatheter aortic valve implantation: what challenge do we face?. Expert Rev Cardiovasc Ther 14 (2016), 381–389.
27. 27 Miller, D.C., Blackstone, E.H., Mack, M.J., et al., for the PARTNER Stroke Substudy Writing Group and Executive Committee. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg 143 (2012), 832–843.e13.
28. 28 Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology European Association for Cardio-Thoracic Surgery, Vahanian, A., et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33 (2012), 2451–2496.
29. 29 Makkar, R.R., Fontana, G., Jilaihawi, H., et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373 (2015), 2015–2024.
30. 30 Rodes-Cabau, J., Kahlert, P., Neumann, F.J., et al. Feasibility and exploratory efficacy evaluation of the Embrella Embolic Deflector system for the prevention of cerebral emboli in patients undergoing transcatheter aortic valve replacement: the PROTAVI-C pilot study. J Am Coll Cardiol Intv 7 (2014), 1146–1155.